Adicet Bio, Inc. (ACET) shareholders
ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
$2.78−0.15 (-5.12%)
Close on Nov 13, 2026Market cap $26.02MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
65.3%
6M of 9M shares
Institutional holders
56
13 new, 6 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
3 buys · 4 sales
Net bought $929.09K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 935,486 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp V LLC (5.90%) | 844,787 | 8.80% | 13D (active) amendment | Apr 8, 2026 |
| Franklin Advisers, Inc. Joint filing with Franklin Templeton, Inc. (7.70%) | 724,138 | 7.70% | 13G (passive) amendment | Sep 30, 2026 |
| Zedek Lauren Marie Joint filing with Zedek Daniel Clayton (5.40%) | 502,309 | 5.40% | 13G (passive) | Oct 19, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACET | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 932,624 | 9.96% | $8.06M | −250,000 | 0.07% |
| Orbimed Advisors LLC | 844,787 | 9.02% | $7.30M | −183,157 | 0.14% |
| Franklin Resources Inc | 626,571 | 6.69% | $5.41M | – | 0.00% |
| Citadel Advisors LLC | 432,738 | 4.62% | $3.74M | +50,915 | 0.00% |
| Vanguard Capital Management LLC | 343,228 | 3.67% | $2.97M | +6,704 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 274,375 | 2.93% | $2.37M | – | 0.00% |
| Renaissance Technologies LLC | 265,945 | 2.84% | $2.30M | +33,354 | 0.00% |
| Stonepine Capital Management, LLC | 245,518 | 2.62% | $2.12M | +23,563 | 1.20% |
| Alyeska Investment Group, L.P. | 203,799 | 2.18% | $1.76M | – | 0.00% |
| Schonfeld Strategic Advisors LLC | 195,514 | 2.09% | $1.69M | New | 0.01% |
| Carlyle Group Inc. | 184,295 | 1.97% | $1.59M | – | 0.02% |
| NEXTBio Capital Management LP | 157,827 | 1.69% | $1.36M | – | 0.63% |
| Acadian Asset Management LLC | 124,832 | 1.33% | $1.08M | +6,694 | 0.00% |
| Two Sigma Investments, LP | 96,839 | 1.03% | $836.69K | +53,733 | 0.00% |
| Geode Capital Management, LLC | 95,634 | 1.02% | $826.70K | −5,501 | 0.00% |
| DAFNA Capital Management LLC | 93,812 | 1.00% | $810.54K | – | 0.15% |
| Bridgeway Capital Management, LLC | 85,959 | 0.92% | $742.69K | New | 0.01% |
| Marshall Wace, Llp | 79,488 | 0.85% | $686.78K | New | 0.00% |
| Trexquant Investment LP | 78,002 | 0.83% | $673.94K | +34,336 | 0.00% |
| Jane Street Group, LLC | 70,561 | 0.75% | $609.65K | +33,477 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 56 | 6M | 65.3% | 13 / 18 | 9 / 6 | 1M | 1M |
| Q1 2026 | 49 | 6M | 68.5% | 12 / 12 | 9 / 11 | 1M | 1M |
| Q4 2025 | 49 | 7M | 72.2% | 15 / 22 | 8 / 20 | 4M | 1M |
| Q3 2025 | 54 | 3M | 34.3% | 12 / 14 | 11 / 7 | 0M | 0M |
| Q2 2025 | 49 | 3M | 34.5% | 10 / 11 | 15 / 17 | 0M | 0M |
| Q1 2025 | 56 | 3M | 37.3% | 4 / 12 | 22 / 12 | 0M | 0M |
| Q4 2024 | 64 | 4M | 38.5% | 7 / 15 | 24 / 7 | 0M | 0M |
| Q3 2024 | 64 | 4M | 38.2% | 8 / 16 | 22 / 29 | 0M | 1M |
| Q2 2024 | 86 | 4M | 42.7% | 18 / 28 | 26 / 30 | 1M | 2M |
| Q1 2024 | 98 | 5M | 55.6% | 32 / 40 | 13 / 11 | 3M | 0M |
| Q4 2023 | 77 | 2M | 24.2% | 8 / 30 | 24 / 14 | 0M | 0M |
| Q3 2023 | 84 | 2M | 23.8% | 13 / 30 | 22 / 23 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
17 funds held ACET in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ACET | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 240,946 | 2.57% | $2.08M | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 225,186 | 2.41% | $2.05M | 0.18% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 98,912 | 1.06% | $854.60K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 85,959 | 0.92% | $742.69K | 0.75% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 47,760 | 0.51% | $444.65K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 23,940 | 0.26% | $206.84K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 17,363 | 0.19% | $161.65K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 14,520 | 0.16% | $132.28K | 0.00% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 14,264 | 0.15% | $129.95K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 12,361 | 0.13% | $115.08K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 4,839 | 0.05% | $45.05K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 2,584 | 0.03% | $22.33K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 1,601 | 0.02% | $13.83K | 0.01% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 1,489 | 0.02% | $12.86K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 786 | 0.01% | $6.79K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lloyd Klickstein | Chief Medical Officer, Director | 108,566 | 1.16% | Aug 7, 2026 |
| Chen Schor | President & CEO, Director | 10,159 | 0.11% | Jun 23, 2026 |
| Blake Aftab | Chief Scientific Officer | 2,981 | 0.03% | Jun 23, 2026 |
| Julia D. Maltzman | Chief Medical Officer | – | – | Mar 27, 2026 |
| Brian Nicholas Harvey | Chief Financial Officer | 5,145 | 0.05% | Mar 27, 2026 |
| Don Healey | Chief Technology Officer | 3,452 | 0.04% | Mar 27, 2026 |
| Andrew Sinclair | Director | 2,133,085 | 22.79% | Jun 23, 2026 |
| Jeffrey Chodakewitz | Director | 17,700 | 0.19% | Jun 23, 2026 |
| Michael Grissinger | Director | – | – | Jun 23, 2026 |
| Katie Peng | Director | 11,800 | 0.13% | Jun 23, 2026 |
| Steve Dubin | Director | 22,700 | 0.24% | Jun 23, 2026 |
| Ra Capital Management, L.P. | 10% owner | – | – | Apr 29, 2026 |
| Peter Kolchinsky | 10% owner | 959,028 | 10.24% | Apr 29, 2026 |
| Rajeev M. Shah | 10% owner | 932,624 | 9.96% | Apr 29, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | 1,182,624 | 12.63% | Apr 29, 2026 |
| OrbiMed Israel GP II, L.P. | 10% owner | 242,285 | 2.59% | Apr 9, 2026 |
| Advisors Llc Orbimed | 10% owner | 4,490,254 | 47.97% | Apr 9, 2026 |
| Capital GP V. LLC OrbiMed | 10% owner | – | – | Apr 9, 2026 |
| Israel BioFund GP Limited Partnership OrbiMed | 10% owner | – | – | Apr 9, 2026 |
| Israel GP Ltd. OrbiMed | 10% owner | 5,243,259 | 56.01% | Apr 9, 2026 |
| Capital GP VI LLC OrbiMed | 10% owner | 292,607 | 3.13% | Apr 9, 2026 |
| Genesis GP LLC OrbiMed | 10% owner | – | – | Apr 9, 2026 |
| Advisors Israel II Ltd OrbiMed | 10% owner | 0 | – | Apr 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rajeev M. Shah 10% owner | Apr 27, 2026 | Other | −250,000 | – | – | 932,624 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 8, 2026 | Sale | −40,416 | $6.52 | $263.51K | 0 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 8, 2026 | Sale | −32,523 | $6.29 | $204.57K | 0 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 7, 2026 | Sale | −2,400 | $6.38 | $15.31K | 32,523 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 7, 2026 | Sale | −29,319 | $6.53 | $191.45K | 34,923 |
| Capital Healthcare Fund LP RA 10% owner | Feb 20, 2026 | Buy | +74,751 | $7.27 | $543.44K | 1,182,624 |
| Capital Healthcare Fund LP RA 10% owner | Feb 19, 2026 | Buy | +74,268 | $7.21 | $535.47K | 1,107,873 |
| Capital Healthcare Fund LP RA 10% owner | Feb 18, 2026 | Buy | +74,577 | $7.04 | $525.02K | 1,033,605 |
| Chen Schor President & CEO, Director | Jan 24, 2026 | Tax withholding | −1,755 | $8.44 | $14.81K | 6,820 |
| Brian Nicholas Harvey Chief Financial Officer | Jan 24, 2026 | Tax withholding | −546 | $8.44 | $4.61K | 5,145 |
| Blake Aftab Chief Scientific Officer | Jan 24, 2026 | Tax withholding | −535 | $8.44 | $4.52K | 2,981 |
| Don Healey Chief Technology Officer | Jan 24, 2026 | Tax withholding | −535 | $8.44 | $4.52K | 3,452 |
| Advisors Llc Orbimed 10% owner | Oct 8, 2025 | Buy | +3,500,000 | $1.00 | $3.50M | 4,490,254 |
| Advisors Llc Orbimed 10% owner | Oct 8, 2025 | Buy | +1,500,000 | $1.00 | $1.50M | 9,026,359 |
| Jeffrey Chodakewitz Director | Jun 11, 2025 | Award | +5,900 | – | – | 17,700 |
| Andrew Sinclair Director | Jun 11, 2025 | Award | +5,900 | – | – | 17,700 |
| Katie Peng Director | Jun 11, 2025 | Award | +5,900 | – | – | 11,800 |
| Steve Dubin Director | Jun 11, 2025 | Award | +5,900 | – | – | 22,700 |
| Lloyd Klickstein Director | Jun 11, 2025 | Award | +5,900 | – | – | 108,566 |
| Don Healey Chief Technology Officer | Jan 24, 2025 | Tax withholding | −8,560 | $0.92 | $7.88K | 63,769 |
| Chen Schor President & CEO, Director | Jan 24, 2025 | Tax withholding | −28,101 | $0.92 | $25.85K | 137,201 |
| Blake Aftab Chief Scientific Officer | Jan 24, 2025 | Tax withholding | −6,270 | $0.92 | $5.77K | 56,241 |
| Brian Nicholas Harvey Chief Financial Officer | Jan 24, 2025 | Tax withholding | −8,752 | $0.92 | $8.05K | 91,048 |
| Carl L. Gordon Director, 10% owner | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Steve Dubin Director | Jun 5, 2024 | Award | +5,900 | – | – | 16,800 |
| Michael Kauffman Director | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Michael Kauffman Director | Jun 5, 2024 | Sale | −5,900 | $1.43 | $8.44K | 5,900 |
| Jeffrey Chodakewitz Director | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Aya Jakobovits Director | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Katie Peng Director | Jun 5, 2024 | Award | +5,900 | – | – | 5,900 |
| Andrew Sinclair Director | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Advisors Israel II Ltd OrbiMed Director, 10% owner | Jan 25, 2024 | Buy | +1,841,100 | $2.40 | $4.42M | 7,526,359 |
| Advisors Israel II Ltd OrbiMed Director, 10% owner | Jan 25, 2024 | Buy | +1,041,700 | $2.40 | $2.50M | 1,255,985 |
| Advisors Israel II Ltd OrbiMed Director, 10% owner | Jan 25, 2024 | Buy | +242,200 | $2.40 | $581.28K | 990,254 |
| Carl L. Gordon Director, 10% owner | Jan 25, 2024 | Buy | +1,841,100 | $2.40 | $4.42M | 7,526,359 |
| Carl L. Gordon Director, 10% owner | Jan 25, 2024 | Buy | +1,041,700 | $2.40 | $2.50M | 1,255,985 |
| Carl L. Gordon Director, 10% owner | Jan 25, 2024 | Buy | +242,200 | $2.40 | $581.28K | 990,254 |
| Blake Aftab Chief Scientific Officer | Jan 24, 2024 | Tax withholding | −3,565 | $2.40 | $8.56K | 42,811 |
| Blake Aftab Chief Scientific Officer | Jan 24, 2024 | Award | +19,700 | – | – | 62,511 |
| Don Healey Chief Technology Officer | Jan 24, 2024 | Tax withholding | −4,870 | $2.40 | $11.69K | 52,629 |
| Don Healey Chief Technology Officer | Jan 24, 2024 | Award | +19,700 | – | – | 72,329 |
| Chen Schor President & CEO, Director | Jan 24, 2024 | Tax withholding | −15,290 | $2.40 | $36.70K | 138,471 |
| Chen Schor President & CEO, Director | Jan 24, 2024 | Award | +70,300 | – | – | 208,771 |
| Francesco Galimi SVP & Chief Medical Officer | Jan 24, 2024 | Tax withholding | −4,957 | $2.40 | $11.90K | 75,501 |
| Francesco Galimi SVP & Chief Medical Officer | Jan 24, 2024 | Award | +26,300 | – | – | 101,801 |
| Brian Nicholas Harvey Chief Financial Officer | Jan 24, 2024 | Tax withholding | −4,320 | $2.40 | $10.37K | 73,500 |
| Brian Nicholas Harvey Chief Financial Officer | Jan 24, 2024 | Award | +26,300 | – | – | 99,800 |
| Blake Aftab Chief Scientific Officer | Oct 12, 2023 | Tax withholding | −7,933 | $1.35 | $10.71K | 46,376 |
| Brian Nicholas Harvey Chief Financial Officer | Oct 2, 2023 | Tax withholding | −7,096 | $1.37 | $9.72K | 77,820 |
| Don Healey Chief Technology Officer | Oct 2, 2023 | Tax withholding | −9,069 | $1.37 | $12.42K | 57,499 |
| Francesco Galimi SVP & Chief Medical Officer | Oct 2, 2023 | Tax withholding | −8,093 | $1.37 | $11.09K | 80,458 |
| Chen Schor President & CEO, Director | Oct 2, 2023 | Buy | +5,500 | $1.33 | $7.32K | 43,469 |
| Chen Schor President & CEO, Director | Oct 2, 2023 | Tax withholding | −23,208 | $1.37 | $31.79K | 153,761 |
| Chen Schor President & CEO, Director | Sep 29, 2023 | Sale | −5,500 | $1.36 | $7.48K | 176,969 |
| Chen Schor President & CEO, Director | Sep 28, 2023 | Buy | +5,500 | $1.42 | $7.81K | 182,469 |
| Chen Schor President & CEO, Director | Sep 28, 2023 | Sale | −5,500 | $1.42 | $7.81K | 37,969 |
| Steve Dubin Director | Jun 30, 2023 | Buy | +5,000 | $2.40 | $12.00K | 10,900 |
| Carl L. Gordon Director, 10% owner | Jun 27, 2023 | Buy | +125,000 | $2.09 | $261.25K | 1,027,885 |
| Carl L. Gordon Director, 10% owner | Jun 27, 2023 | Buy | +250,000 | $2.09 | $522.50K | 646,657 |
| Carl L. Gordon Director, 10% owner | Jun 27, 2023 | Buy | +442,000 | $2.09 | $923.78K | 5,685,259 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
64.22%
0M shares short
Days to cover
2.6
At 0M shares a day
Change since last report
-11.9%
From 1M shares
Short volume, 20 days
38.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Adicet Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 13,802 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| OrbiMed Genesis Master Fund, L.P. Shareholder | Apr 9, 2026 | 78,499 | $514.17K | Apr 9, 2026 | Public Offering |
| OrbiMed Israel Partners II, L.P. Shareholder | Apr 8, 2026 | 40,416 | $264.72K | Apr 8, 2026 | Merger |
| OrbiMed Israel Partners Limited Partnership Shareholder | Apr 7, 2026 | 64,242 | $413.08K | Apr 7, 2026 | Merger |
| Michael Kauffman Director | Jun 5, 2024 | 5,900 | $8.44K | Jun 5, 2024 | RESTRICTED STOCK |
| Chen Schor Officer, Director | Sep 29, 2023 | 5,500 | $7.48K | Sep 29, 2023 | Performance Stock Units |
See a number that looks wrong?